| scholarly article | Q13442814 |
| P50 | author | Victor Velculescu | Q7926425 |
| Francesco Galimi | Q84074916 | ||
| Giorgia Migliardi | Q84074917 | ||
| Livio Trusolino | Q88370775 | ||
| Sebastijan Hobor | Q114382104 | ||
| Mark Sausen | Q116781886 | ||
| Andrea Cassingena | Q117234514 | ||
| Marcello Gambacorta | Q117804625 | ||
| Calogero Lauricella | Q117805144 | ||
| Elisa Scala | Q117805150 | ||
| Davide Zecchin | Q117805151 | ||
| Federica Di Nicolantonio | Q28321686 | ||
| Alberto Bardelli | Q28321691 | ||
| Andrea Sartore-Bianchi | Q28321693 | ||
| Salvatore Siena | Q28321703 | ||
| Paolo M. Comoglio | Q37381902 | ||
| Andrea Bertotti | Q37831180 | ||
| Silvio Marco Veronese | Q39051644 | ||
| Luis Alberto Diaz Jr | Q52152141 | ||
| Giulia Siravegna | Q56862949 | ||
| Simona Corso | Q56872439 | ||
| Silvia Giordano | Q56872444 | ||
| Emanuele Valtorta | Q57018578 | ||
| Giorgio Corti | Q58376404 | ||
| A Amatu | Q82728305 | ||
| P2093 | author name string | Timothy Perera | |
| Carlo Zanon | |||
| Maria Apicella | |||
| P2860 | cites work | Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab | Q24600031 |
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 | ||
| Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma | Q24630017 | ||
| Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer | Q27851407 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer | Q27851708 | ||
| A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | Q27851787 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Development of personalized tumor biomarkers using massively parallel sequencing | Q28278819 | ||
| Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing | Q28280303 | ||
| KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy | Q28285473 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| Liver regeneration | Q29614743 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| EGFR antagonists in cancer treatment | Q29616740 | ||
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion | Q29617359 | ||
| Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. | Q34032640 | ||
| Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy | Q34068262 | ||
| Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin | Q34212131 | ||
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. | Q34307548 | ||
| HGF rescues colorectal cancer cells from EGFR inhibition via MET activation | Q34550898 | ||
| Drug development of MET inhibitors: targeting oncogene addiction and expedience | Q34782774 | ||
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Q35666332 | ||
| Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia | Q36223356 | ||
| Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer | Q36614114 | ||
| Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients | Q36755257 | ||
| MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. | Q37321772 | ||
| MET signalling: principles and functions in development, organ regeneration and cancer | Q37811895 | ||
| Targeting MET in cancer: rationale and progress | Q37978193 | ||
| MET: a promising anticancer therapeutic target | Q38008247 | ||
| PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab | Q38584695 | ||
| Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas | Q39384830 | ||
| Nuclear EGFR contributes to acquired resistance to cetuximab | Q39812008 | ||
| Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. | Q39887931 | ||
| Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons | Q41115353 | ||
| Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET | Q41152225 | ||
| Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. | Q42454085 | ||
| Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists | Q42810535 | ||
| A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. | Q46454840 | ||
| Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study | Q46465639 | ||
| Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma | Q46856639 | ||
| A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. | Q52832708 | ||
| Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? | Q54361260 | ||
| Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations | Q56688160 | ||
| c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype | Q77583076 | ||
| Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab | Q81098062 | ||
| Genetic heterogeneity and cancer drug resistance | Q83791245 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 658-673 | |
| P577 | publication date | 2013-06-02 | |
| P1433 | published in | Cancer Discovery | Q15724440 |
| P1476 | title | Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer | |
| P478 | volume | 3 |
| Q43200018 | 4th international conference on tumor progression and therapeutic resistance: meeting report |
| Q53682041 | A Convergence-Based Framework for Cancer Drug Resistance. |
| Q30316105 | A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer |
| Q47145975 | A Small Molecule Inhibitor of the β-Catenin-TCF4 Interaction Suppresses Colorectal Cancer Growth In Vitro and In Vivo. |
| Q28069867 | A perspective on anti-EGFR therapies targeting triple-negative breast cancer |
| Q37352435 | A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy |
| Q58771181 | A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification |
| Q39120801 | Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. |
| Q36571455 | Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. |
| Q27022741 | Acquired resistance to EGFR-targeted therapies in colorectal cancer |
| Q35658282 | Activating MET kinase rearrangements in melanoma and Spitz tumours |
| Q34463388 | Activation of RAS family members confers resistance to ROS1 targeting drugs. |
| Q38363739 | Adaptive stress signaling in targeted cancer therapy resistance |
| Q57300306 | Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis |
| Q26751344 | Advances in targeted and immunobased therapies for colorectal cancer in the genomic era |
| Q26748924 | Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer |
| Q60044604 | Advantage of Next-Generation Sequencing in Dynamic Monitoring of Circulating Tumor DNA over Droplet Digital PCR in Cetuximab Treated Colorectal Cancer Patients |
| Q39037450 | An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics |
| Q104617809 | An insight into small extracellular vesicles: Their roles in colorectal cancer progression and potential clinical applications |
| Q34418393 | An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth |
| Q35222611 | Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit |
| Q38219290 | Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories |
| Q97525750 | Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance |
| Q46744252 | Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. |
| Q97538351 | Applications of cell-free circulating tumor DNA detection in EGFR mutant lung cancer |
| Q49163920 | Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment |
| Q35674206 | Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer. |
| Q54978430 | BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC. |
| Q97525759 | BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy |
| Q42499937 | Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates |
| Q38222512 | Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer |
| Q26766535 | Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS |
| Q51752412 | Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. |
| Q38699032 | Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients |
| Q28239638 | Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA |
| Q42933363 | Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer |
| Q64246955 | Broad-spectrum receptor tyrosine kinase inhibitors overcome and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer |
| Q60912537 | CD44v6 engages in colorectal cancer progression |
| Q36340540 | CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells |
| Q89966984 | Caveolin-1 Promotes Chemoresistance of Gastric Cancer Cells to Cisplatin by Activating WNT/β-Catenin Pathway |
| Q58698130 | Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer |
| Q26750899 | Cell-free circulating tumor DNA in cancer |
| Q39899490 | Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. |
| Q61867703 | Cetuximab or bevacizumab in metastatic colorectal cancer? |
| Q33580500 | Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells |
| Q38827897 | Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory |
| Q35133788 | Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. |
| Q35218647 | Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment |
| Q58114470 | Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review |
| Q33632125 | Circulating Tumor DNA as Biomarkers for Cancer Detection |
| Q91742610 | Circulating tumor DNA in colorectal cancer: opportunities and challenges |
| Q38261856 | Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? |
| Q38800475 | Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology |
| Q42093061 | Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma |
| Q54980136 | Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. |
| Q54849840 | Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. |
| Q42183079 | Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. |
| Q38652194 | Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation |
| Q36257068 | Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma |
| Q64111464 | Combination of cetuximab with met inhibitor in control of cetuximab-resistant oral squamous cell carcinoma |
| Q92522562 | Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models |
| Q90044630 | Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status |
| Q38648453 | Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer |
| Q39066439 | Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer |
| Q40971143 | Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells |
| Q93039741 | Current Development of Monoclonal Antibodies in Cancer Therapy |
| Q90702159 | Current advances of targeting HGF/c-Met pathway in gastric cancer |
| Q89993964 | Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research |
| Q91830988 | Current and emerging biomarkers in metastatic colorectal cancer |
| Q33861210 | Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients |
| Q54941802 | Detecting Disease Specific Pathway Substructures through an Integrated Systems Biology Approach. |
| Q89896773 | Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients |
| Q47911980 | Detection of MET mRNA in gastric cancer in situ. Comparison with immunohistochemistry and sandwich immunoassays |
| Q53765363 | Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies. |
| Q38912279 | Development of antibody-based c-Met inhibitors for targeted cancer therapy |
| Q26769649 | Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive |
| Q46213853 | Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer |
| Q38728221 | Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer |
| Q38218657 | Drug resistance to targeted therapies: déjà vu all over again |
| Q42282846 | Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody. |
| Q41116584 | Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer |
| Q90664789 | Dynamic Treatment Stratification Using ctDNA |
| Q40157506 | Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. |
| Q49887890 | EGFR-TKIs resistance via EGFR-independent signaling pathways |
| Q35666148 | ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer |
| Q48501675 | Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial |
| Q38706872 | Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer |
| Q88549071 | Emerging Systemic Therapies for Colorectal Cancer |
| Q33769437 | Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors |
| Q38892107 | Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells |
| Q41783185 | Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report. |
| Q37532630 | Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. |
| Q55380373 | Establishing and Maintaining an Extensive Library of Patient-Derived Xenograft Models. |
| Q38319572 | Evolution of targeted therapies in cancer: opportunities and challenges in the clinic |
| Q48500250 | Examining the utility of patient-derived xenograft mouse models |
| Q97539272 | Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges |
| Q35017808 | Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma |
| Q37706176 | Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells |
| Q38685749 | Future perspectives of circulating tumor DNA in colorectal cancer. |
| Q33808741 | Game theory in the death galaxy: interaction of cancer and stromal cells in tumour microenvironment |
| Q37317530 | Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab |
| Q36700258 | Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients |
| Q28079323 | Genetically engineered mouse models in oncology research and cancer medicine |
| Q41911703 | Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations |
| Q91743984 | Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer |
| Q90950820 | Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients |
| Q26739052 | Genomic diversity of colorectal cancer: Changing landscape and emerging targets |
| Q46334692 | Genomic landscape of cell-free DNA in patients with colorectal cancer. |
| Q38249332 | Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance |
| Q27853193 | HER2 activating mutations are targets for colorectal cancer treatment |
| Q36772167 | HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer |
| Q38831784 | Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment |
| Q64104915 | Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures |
| Q49832628 | Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced cancers of the gastrointestinal tract or anus. |
| Q41511106 | IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. |
| Q35747784 | Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein |
| Q36310845 | In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer |
| Q38976616 | Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence |
| Q49218679 | Inhibition of integrin β1-mediated oncogenic signalling by the antitumor microRNA-29 family in head and neck squamous cell carcinoma |
| Q38859217 | Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. |
| Q42822334 | Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. |
| Q39157824 | Integrating liquid biopsies into the management of cancer |
| Q47301172 | Interplay of autophagy, receptor tyrosine kinase signalling and endocytic trafficking |
| Q39095733 | Interrogating open issues in cancer precision medicine with patient-derived xenografts. |
| Q48181330 | KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. |
| Q38136134 | KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. |
| Q26751212 | Kirsten Ras* oncogene: Significance of its discovery in human cancer research |
| Q52318134 | Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. |
| Q33576849 | Latest progress in tyrosine kinase inhibitors |
| Q39047616 | Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies |
| Q41909644 | Linking oncogenesis and immune system evasion in acquired resistance to EGFR-targeting antibodies: Lessons from a preclinical model |
| Q64241627 | Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications |
| Q64947645 | Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. |
| Q34708926 | MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. |
| Q91789111 | MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis |
| Q42317509 | MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon |
| Q26781054 | MET deregulation in breast cancer |
| Q34971893 | MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors |
| Q89603062 | MET targeting: time for a rematch |
| Q37682961 | MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. |
| Q96230891 | MET-dependent solid tumours - molecular diagnosis and targeted therapy |
| Q38675350 | MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. |
| Q92537377 | MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM |
| Q40026210 | MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. |
| Q90311685 | Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells |
| Q28074073 | Mechanisms of resistance to anti-EGFR therapy in colorectal cancer |
| Q28076490 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer |
| Q91361655 | Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours |
| Q35141465 | Met receptor-induced Grb2 or Shc signals both promote transformation of intestinal epithelial cells, albeit they are required for distinct oncogenic functions |
| Q38705019 | Modeling of Patient-Derived Xenografts in Colorectal Cancer |
| Q64076854 | Molecular Profiling of Druggable Targets in Clear Cell Renal Cell Carcinoma Through Targeted RNA Sequencing |
| Q37710556 | Molecular Testing for Gastrointestinal Cancer. |
| Q40120812 | Molecular classification of colorectal cancer: Current perspectives and controversies |
| Q35761956 | Molecular markers predictive of chemotherapy response in colorectal cancer |
| Q28070583 | Molecular predictive markers in tumors of the gastrointestinal tract |
| Q41091941 | Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience |
| Q98386286 | Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer |
| Q42953876 | Monitoring cancer through the blood |
| Q58776633 | Mouse models in the era of large human tumour sequencing studies |
| Q40808615 | Multiple differential expression networks identify key genes in rectal cancer |
| Q90190001 | Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy |
| Q50089419 | Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study |
| Q26796348 | New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? |
| Q36432094 | Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer |
| Q38759141 | Novel anti-angiogenic therapeutic strategies in colorectal cancer |
| Q38846778 | PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells. |
| Q92482532 | PRSS contributes to cetuximab resistance in colorectal cancer |
| Q38167675 | Palliative treatment of metastatic colorectal cancer: what is the optimal approach? |
| Q60960810 | Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases |
| Q47161111 | Patient-derived Xenografts from Colorectal Carcinoma: A Temporal and Hierarchical Study of Murine Stromal Cell Replacement |
| Q26741651 | Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review |
| Q34205518 | Patient-derived xenograft models: an emerging platform for translational cancer research |
| Q90573200 | Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment |
| Q30379025 | Patients with genetically heterogeneous synchronous colorectal cancer carry rare damaging germline mutations in immune-related genes. |
| Q39453553 | Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies |
| Q38363276 | Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies |
| Q28076200 | Pharmacogenetics and pharmacogenomics as tools in cancer therapy |
| Q28080730 | Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond |
| Q38269777 | Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. |
| Q26769850 | Pharmacologic resistance in colorectal cancer: a review |
| Q38891575 | Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. |
| Q90292848 | Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer |
| Q39223563 | Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. |
| Q27853074 | Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. |
| Q38805790 | Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer |
| Q50195535 | Precision Oncology: The Road Ahead. |
| Q50096902 | Preclinical mouse solid tumour models: status quo, challenges and perspectives. |
| Q58120155 | Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer |
| Q34564071 | Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors |
| Q27015224 | Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies |
| Q33895573 | Primary and acquired resistance to biologic therapies in gastrointestinal cancers |
| Q36028658 | Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study |
| Q26771952 | Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer |
| Q41073453 | Prognostic Value of C-met Expression in Cholangiocarcinoma |
| Q36115580 | Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy |
| Q55031644 | Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma. |
| Q37175089 | Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies |
| Q38502350 | Promise and challenges on the horizon of MET-targeted cancer therapeutics |
| Q33356339 | Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together! |
| Q38918710 | Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification |
| Q35859573 | Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring Assays |
| Q28074175 | RAS and BRAF in metastatic colorectal cancer management |
| Q35212113 | Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer |
| Q39456851 | Re-Evaluating Clonal Dominance in Cancer Evolution |
| Q39147121 | Realizing the potential of plasma genotyping in an age of genotype-directed therapies. |
| Q33624491 | Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer |
| Q92578812 | Resistance to TRK inhibition mediated by convergent MAPK pathway activation |
| Q36189390 | Resistance to targeted cancer drugs through hepatocyte growth factor signaling |
| Q90083939 | Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer |
| Q91644121 | Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now? |
| Q57050008 | Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation |
| Q38516244 | Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. |
| Q53711253 | Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. |
| Q38134309 | Role of cMET in the development and progression of colorectal cancer |
| Q39051652 | Role of circulating free DNA in colorectal cancer |
| Q27027957 | Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents |
| Q36400301 | SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. |
| Q100526068 | SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET |
| Q36782629 | Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer |
| Q33682988 | Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer |
| Q53164323 | Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. |
| Q26783920 | Single and Multiple Gene Manipulations in Mouse Models of Human Cancer |
| Q38151570 | Somatic alterations as the basis for resistance to targeted therapies |
| Q36137109 | Spheroid Culture of Head and Neck Cancer Cells Reveals an Important Role of EGFR Signalling in Anchorage Independent Survival |
| Q44283525 | Study of MET protein levels and MET gene copy number in 72 sinonasal intestinal-type adenocarcinomas |
| Q52576043 | Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models. |
| Q61867795 | Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial |
| Q92306520 | Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review |
| Q49961144 | Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma |
| Q38390840 | Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. |
| Q38856729 | Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges |
| Q38216590 | Targeting the oncogenic Met receptor by antibodies and gene therapy |
| Q57175806 | The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies |
| Q92193162 | The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer |
| Q26777125 | The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy |
| Q91737758 | The Role Of Circulating Tumor DNA In Therapeutic Resistance |
| Q58566840 | The Role of PI3K in Met Driven Cancer: A Recap |
| Q37548858 | The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies |
| Q38724312 | The State of the Art in Colorectal Cancer Molecular Biomarker Testing |
| Q91869042 | The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer |
| Q58799989 | The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer |
| Q35068059 | The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells |
| Q91341298 | The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches |
| Q39274990 | The c-Met receptor: Implication for targeted therapies in colorectal cancer |
| Q92085863 | The design, analysis and application of mouse clinical trials in oncology drug development |
| Q36930106 | The genomic landscape of response to EGFR blockade in colorectal cancer. |
| Q53832823 | The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience. |
| Q26781693 | The influence of subclonal resistance mutations on targeted cancer therapy |
| Q38880745 | The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets |
| Q52316580 | The multiple paths towards MET receptor addiction in cancer. |
| Q90091971 | The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer |
| Q42139529 | Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation |
| Q28071772 | Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence |
| Q93080796 | Towards Circulating-Tumor DNA-Based Precision Medicine |
| Q64997832 | Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab. |
| Q27022954 | Treatment of metastatic colorectal cancer: focus on panitumumab |
| Q39176607 | Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution |
| Q41660598 | Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain. |
| Q26866803 | Tumour heterogeneity and the evolution of polyclonal drug resistance |
| Q38265382 | Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology |
| Q90211933 | VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells |
| Q38833684 | Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. |
| Q55070676 | [Thirty years of Met receptor research: from the discovery of an oncogene to the development of targeted therapies]. |
| Q26775483 | c-Met as a Target for Personalized Therapy |
| Q42509388 | mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism |
Search more.